This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
CADTH. Celecoxib versus non-selective non-steroidal anti-Inflammatory drugs and proton pump inhibitors: clinical effectiveness, safety, and cost-effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2011
Limited evidence showed that celecoxib versus non-COX-2 selective non-steroidal anti-inflammatory drugs (nsNSAIDs) and proton pumps inhibitors (PPIs) had a similar clinical efficacy and safety profile. nsNSAIDs plus PPIs may be marginally more cost-effective versus celecoxib in the management of adult patients with rheumatoid arthritis or osteoarthritis.
Subject indexing assigned by CRD
Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase 2 Inhibitors; Osteoarthritis; Pain; Proton Pump Inhibitors; Pyrazoles; Sulfonamidess
Country of organisation
An English language summary is available.
Address for correspondence
Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, K1S 5S8 Ottawa, Ontario Canada Email: email@example.com
Date abstract record published